Nikolaos Mitrousis, PhD
Nick received a BSc in molecular biology and genetics from the Democritus University of Thrace in Greece. He completed his PhD in biomedical engineering at the University of Toronto, Canada, and is currently a postdoctoral research fellow in the Hubbell and Swartz labs.
Radiotherapy (RT) is used in more than 50% of cancer patients clinically, however, it does not typically lead to curative responses. The Swartz lab has previously identified that lymphangiogenesis can potentiate anti-tumor immune responses.
In this project, we are exploring the role of lymphangiogenesis in the anti-tumor efficacy of RT. Our goals are two-fold: i) to gain biological understanding of the immune effects of lymphangiogenesis in the context of RT, and ii) to develop novel therapeutics that increase the efficacy of RT, based on lymphangiogenesis.